Tilray Q2 preview: Where next for TLRY stock?

Tilray shares have lost almost 90% of their value since hitting all-time highs 11 months ago. Can the cannabis stock revive its fortunes when it releases earnings next week?

When will Tilray release Q2 earnings?

Tilray will publish second quarter earnings covering the three months to the end of November 2021 before US markets open on Monday January 10.


Tilray Q2 earnings preview: what to expect from the results

Wall Street is currently expecting Tilray to report the following numbers in the second quarter. Year-ago comparisons have not been provided due to the change in Tilray’s financial year following the merger with Aphria last year, which means the second quarter’s timeframe does not align with the results posted last year. However, the results from the previous quarter have been supplied for context.

  • Revenue of $172.6 million (vs $168 million in Q1)
  • Adjusted Ebitda of $14.0 million (vs $12.7 million in Q1)
  • A net loss of $36.2 million (vs a $34.6 million loss in Q1)

Cannabis revenue, which accounts for over 40% of total income, is expected to drive topline growth in the quarter as sales should benefit from the reopening of legalised marijuana retail stores in Canada since mid-June when Covid restrictions started to ease. However, this will be closely-watched considering competition is intensifying and the battle is being fought using prices.

Meanwhile, revenue from alcohol sales by its SweetWater brand and wellness, CBD and hemp product sales through Manitoba Harvest, as well as income from distribution activities, are all expected to remain broadly in-line with what was delivered in the previous quarter. Therefore, cannabis sales are likely to be the deciding factor as to whether Tilray can beat topline expectations this time around, having narrowly missed them during the last two quarters.

Tilray is expected to deliver its 11th consecutive quarter of positive adjusted Ebitda, although its net loss at the bottom-line is expected to widen slightly from the previous quarter. Notably, Tilray purchased Breckenridge Distillery in the US last month and said this would provide an immediate boost to Ebitda going forward. The business is known for its bourbon whiskey and portfolio of craft spirits and is being folded into SweetWater.

Tilray completed its merger with Aphria in May 2021 and the enlarged company has already locked-in $55 million of annual run-rate cost savings so far. Investors will be keen to know what progress has been made as Aphria continues to be integrated into Tilray. Once synergies are realised, the company has said this should rise to around $80 million going forward. The merger has improved scale and helped Tilray stay in the black at the adjusted Ebitda level over the last year – in fact, the company said adjusted Ebitda would have been as high as $17 million in the first quarter if normalised for Aphria’s production costs, showing the potential boost it could provide going forward.

The merger has also cemented Tilray as the leading cannabis company in Canada and helped solidify itself as one of the market leaders overseas. For example, it is already the largest player in the medicinal market in the key European market of Germany. Tilray is also among the companies best positioned to capitalise should marijuana be legalised at the federal level in the US – which is the number one trigger that the global market is eagerly awaiting to be pulled. It has convertible notes in US player MedMen which will convert into shares should the US give the green light.


Where next for TLRY stock?

Tilray shares have been trending lower over the last six months and currently trade at their lowest level in 13 months. If the current trend persists, we could see the stock continue to slide toward $6. Levels suggest there is sizeable downside potential, first to the $4.50 that provided support back in September 2020.

On the upside, the first target is the 50-day sma at $9.72 and then the 100-day sma at $10.88, which is in-line with the tentative 6-month trendline that started in June. The RSI is currently bearish but has recently slipped into oversold territory, and volumes have trended higher over the first week of 2022.

Where next for the Tilray share price?

(Source: Eikon)

The 20 brokers that cover Tilray have an average target price of $11.44 – implying there is over 70% potential upside from the current share price following the heavy selloff over the last seven months.


How to trade Tilray stock

You can trade Tilray shares with City Index in just four easy steps:

  1. Open a City Index account, or log-in if you’re already a customer.
  2. Search for ‘Tilray’ in our award-winning platform
  3. Choose your position and size, and your stop and limit levels
  4. Place the trade

Build your confidence risk free
Join our live webinars for the latest analysis and trading ideas. Register now

StoneX Financial Ltd (trading as “City Index”) is an execution-only service provider. This material, whether or not it states any opinions, is for general information purposes only and it does not take into account your personal circumstances or objectives. This material has been prepared using the thoughts and opinions of the author and these may change. However, City Index does not plan to provide further updates to any material once published and it is not under any obligation to keep this material up to date. This material is short term in nature and may only relate to facts and circumstances existing at a specific time or day. Nothing in this material is (or should be considered to be) financial, investment, legal, tax or other advice and no reliance should be placed on it.

No opinion given in this material constitutes a recommendation by City Index or the author that any particular investment, security, transaction or investment strategy is suitable for any specific person. The material has not been prepared in accordance with legal requirements designed to promote the independence of investment research. Although City Index is not specifically prevented from dealing before providing this material, City Index does not seek to take advantage of the material prior to its dissemination. This material is not intended for distribution to, or use by, any person in any country or jurisdiction where such distribution or use would be contrary to local law or regulation.

For further details see our full non-independent research disclaimer and quarterly summary.